Pacira BioSciences, Inc. (PCRX) Key Metrics
PCRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.45B
- Enterprise value
- $1.14B
- P/E (TTM)
- 103.8 10-yr median 65.4
- Forward P/E
- 6.2
- PEG ratio
- 11.21
- Price / sales
- 1.9 10-yr median 4.4
- Price / book
- 1.5 10-yr median 4.0
- EV / EBITDA
- 9.8 10-yr median 31.7
- Dividend yield
- —
- Beta
- 0.25
PCRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPCRX valuation Price multiples at each fiscal year-end price.
PCRX returns How much profit the business earns on the capital it uses.
PCRX per-share figures Results divided by the shares outstanding at year-end.
PCRX financial health Debt, liquidity and how easily interest is covered.
PCRX efficiency & capital use Working capital cycle and where the cash goes.
PCRX valuation history
PCRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PCRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PCRX cash returned to shareholders
PCRX price vs earnings per share
PCRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.17B | $871.3M | $1.75B | $1.80B | $2.75B | $2.61B | $1.88B | $1.76B | $1.82B | $1.20B |
| Enterprise value | $1.38B | $1.03B | $2.06B | $2.27B | $3.22B | $2.63B | $1.94B | $1.67B | $1.78B | $1.14B |
| P/E ratio | 165.7 | — | 41.8 | 112.9 | 65.4 | 18.0 | — | — | — | — |
| Price / sales | 1.6 | 1.2 | 2.6 | 2.7 | 5.1 | 6.1 | 4.5 | 5.2 | 6.3 | 4.4 |
| Price / book | 1.7 | 1.1 | 2.0 | 2.3 | 3.8 | 4.2 | 5.3 | 5.5 | 6.5 | 5.5 |
| Price / free cash flow | 8.5 | 4.9 | 12.6 | 15.6 | 34.4 | 66.6 | 31.2 | 51.2 | — | 137.5 |
| Price / operating cash flow | 7.7 | 4.6 | 11.3 | 12.4 | 21.8 | 33.9 | 26.7 | 36.0 | 102.2 | 36.0 |
| EV / sales | 1.9 | 1.5 | 3.1 | 3.4 | 5.9 | 6.1 | 4.6 | 4.9 | 6.2 | 4.1 |
| EV / EBITDA | 11.3 | 35.2 | 13.3 | 16.2 | 28.2 | 41.5 | 63.1 | 50.4 | — | — |
| EV / free cash flow | 10.1 | 5.7 | 14.8 | 19.7 | 40.3 | 67.1 | 32.1 | 48.5 | — | 130.2 |
| Earnings yield | 0.6% | −11.4% | 2.4% | 0.9% | 1.5% | 5.6% | −0.6% | −0.0% | −2.3% | −3.2% |
| Free cash flow yield | 11.7% | 20.5% | 8.0% | 6.4% | 2.9% | 1.5% | 3.2% | 2.0% | −0.1% | 0.7% |
| Dividend yield | — | — | 0.2% | — | 0.1% | 0.1% | 0.2% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 12.7% | 2.9% | 0.2% | 0.0% | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $25.88 | $18.84 | $33.74 | $38.61 | $60.17 | $59.84 | $45.30 | $43.02 | $45.65 | $32.30 |
| Per share | ||||||||||
| Revenue per share | $16.13 | $15.16 | $12.99 | $14.33 | $11.87 | $9.84 | $10.14 | $8.24 | $7.20 | $7.42 |
| Earnings per share | $0.16 | −$2.15 | $0.81 | $0.34 | $0.92 | $3.33 | −$0.27 | −$0.01 | −$1.07 | −$1.02 |
| Operating cash flow per share | $3.37 | $4.10 | $2.98 | $3.12 | $2.76 | $1.76 | $1.70 | $1.19 | $0.45 | $0.90 |
| Free cash flow per share | $3.03 | $3.87 | $2.68 | $2.48 | $1.75 | $0.90 | $1.45 | $0.84 | −$0.04 | $0.23 |
| Cash per share | $5.29 | $10.48 | $5.36 | $6.20 | $14.39 | $11.94 | $7.03 | $9.37 | $7.82 | $4.64 |
| Book value per share | $15.39 | $16.83 | $16.74 | $16.65 | $16.01 | $14.19 | $8.55 | $7.85 | $7.02 | $5.88 |
| Tangible book value per share | $6.77 | $7.62 | $4.30 | $1.53 | −$0.85 | $9.70 | $3.64 | $6.34 | $4.25 | $3.37 |
| Dividends per share | — | — | $0.05 | — | $0.06 | $0.04 | $0.10 | — | $0.00 | $0.00 |
| Capex per share | $0.34 | $0.23 | $0.29 | $0.65 | $1.01 | $0.87 | $0.24 | $0.35 | $0.48 | $0.66 |
| Debt per share | $10.09 | $13.81 | $11.27 | $16.40 | $24.74 | $12.39 | $8.48 | $7.11 | $6.95 | $2.92 |
| Shares outstanding | 45.0M | 46.2M | 52.0M | 46.5M | 45.6M | 43.7M | 41.5M | 40.9M | 39.8M | 37.2M |
| Change in shares outstanding | −2.6% | −11.0% | +11.7% | +2.0% | +4.5% | +5.2% | +1.5% | +2.8% | +6.9% | −9.8% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 1.0% | −12.1% | 5.1% | 2.1% | 6.2% | 29.9% | −3.3% | −0.2% | −17.1% | −17.4% |
| Return on invested capital (ROIC) | 1.8% | −5.5% | 4.9% | 4.9% | 7.3% | 8.8% | 2.6% | 5.3% | −9.9% | −15.8% |
| Return on assets (ROA) | 0.5% | −6.4% | 2.6% | 0.8% | 2.5% | 13.8% | −1.4% | −0.1% | −8.4% | −9.7% |
| Return on tangible assets | 0.8% | −8.8% | 4.5% | 1.6% | 3.2% | 13.5% | −1.8% | −0.1% | −8.2% | −12.7% |
| Free cash flow margin | 18.8% | 25.5% | 20.7% | 17.3% | 14.7% | 9.1% | 14.3% | 10.2% | −0.5% | 3.2% |
| Income quality (OCF / net income) | 21.61 | — | 3.69 | 9.13 | 2.99 | 0.53 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $454.4M | $638.9M | $586.0M | $763.4M | $1.13B | $541.1M | $351.9M | $290.9M | $276.5M | $108.7M |
| Cash & short-term investments | $238.4M | $484.6M | $278.6M | $288.7M | $656.4M | $521.7M | $291.9M | $383.5M | $311.3M | $172.6M |
| Net debt | $216.0M | $154.2M | $307.5M | $474.7M | $472.4M | $19.5M | $60.0M | −$92.5M | −$34.9M | −$63.9M |
| Debt / equity | 0.66 | 0.82 | 0.67 | 0.99 | 1.55 | 0.87 | 0.99 | 0.91 | 0.99 | 0.50 |
| Debt / assets | 0.36 | 0.41 | 0.37 | 0.45 | 0.54 | 0.42 | 0.42 | 0.42 | 0.44 | 0.28 |
| Net debt / EBITDA | 1.76 | 5.30 | 1.99 | 3.38 | 4.15 | 0.31 | 1.95 | −2.80 | — | — |
| Current ratio | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 | 2.57 | 3.79 | 7.88 | 6.96 | 5.42 |
| Quick ratio | 3.28 | 2.00 | 4.17 | 2.72 | 1.47 | 2.32 | 3.25 | 7.08 | 6.22 | 4.72 |
| Interest coverage | 2.3 | -4.4 | 5.1 | 1.7 | 3.1 | 1.8 | 0.4 | 0.7 | -1.4 | -4.5 |
| Working capital | $427.4M | $435.2M | $412.6M | $350.6M | $344.9M | $398.3M | $300.9M | $417.3M | $334.9M | $198.3M |
| Invested capital | $909.1M | $932.6M | $1.18B | $1.25B | $1.20B | $639.2M | $414.9M | $228.7M | $244.6M | $155.1M |
| Tangible asset value | $304.8M | $352.4M | $223.6M | $71.2M | −$38.7M | $423.6M | $151.0M | $259.2M | $169.1M | $125.5M |
| Net current asset value | −$23.8M | −$30.0M | −$194.3M | −$407.9M | −$478.9M | −$3.2M | −$67.6M | $109.8M | $42.2M | $70.6M |
| Graham number | $7.35 | — | $17.44 | $11.32 | $18.20 | $32.61 | — | — | — | — |
| Graham net-net per share | −$3.64 | −$3.09 | −$5.66 | −$10.65 | −$12.43 | −$1.40 | −$2.88 | $1.66 | $0.17 | $1.03 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $2.8M | — | $2.7M | $1.6M | $4.3M | — | $0 | $0 |
| Share buybacks (net) | $148.3M | $25.0M | $106,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividend payout ratio | — | — | 6.7% | — | 6.4% | 1.1% | — | — | — | — |
| Dividends + buybacks / free cash flow | 108.5% | 14.0% | 2.1% | 0.0% | 3.3% | 4.1% | 7.1% | 0.0% | — | 0.0% |
| Capex / revenue | 2.1% | 1.5% | 2.2% | 4.5% | 8.5% | 8.8% | 2.4% | 4.3% | 6.7% | 8.9% |
| Capex / operating cash flow | 10.1% | 5.6% | 9.8% | 20.7% | 36.5% | 49.1% | 14.4% | 29.7% | 108.3% | 73.9% |
| Capex / depreciation | 0.17 | 0.14 | 0.20 | 0.33 | 1.61 | 1.90 | 0.52 | 1.10 | 1.39 | 1.91 |
| Stock-based compensation / revenue | 7.9% | 7.3% | 7.1% | 7.2% | 7.8% | 9.3% | 8.0% | 9.4% | 11.0% | 11.3% |
| R&D / revenue | 16.1% | 11.6% | 11.3% | 12.7% | 10.3% | 13.8% | 17.1% | 16.5% | 20.0% | 16.5% |
| SG&A / revenue | 50.8% | 42.0% | 39.9% | 38.2% | 36.8% | 45.0% | 47.7% | 52.6% | 56.3% | 55.2% |
| Efficiency | ||||||||||
| Days sales outstanding | 59.6 | 57.0 | 55.1 | 53.3 | 50.3 | 42.7 | 37.1 | 37.7 | 39.2 | 36.8 |
| Days of inventory on hand | 339.0 | 245.9 | 198.1 | 178.2 | 212.4 | 191.2 | 182.8 | 189.1 | 150.9 | 154.0 |
| Days payables outstanding | 41.8 | 37.3 | 30.6 | 23.6 | 27.3 | 36.1 | 46.5 | 61.0 | 46.0 | 26.9 |
| Cash conversion cycle (days) | 356.8 | 265.6 | 222.7 | 207.9 | 235.4 | 197.8 | 173.4 | 165.8 | 144.1 | 163.9 |
| Receivables turnover | 6.12 | 6.41 | 6.62 | 6.85 | 7.25 | 8.54 | 9.85 | 9.68 | 9.31 | 9.91 |
| Payables turnover | 8.74 | 9.79 | 11.95 | 15.47 | 13.37 | 10.10 | 7.86 | 5.98 | 7.93 | 13.55 |
| Inventory turnover | 1.08 | 1.48 | 1.84 | 2.05 | 1.72 | 1.91 | 2.00 | 1.93 | 2.42 | 2.37 |
| Asset turnover | 0.52 | 0.45 | 0.41 | 0.36 | 0.32 | 0.41 | 0.55 | 0.51 | 0.56 | 0.71 |
| Average receivables | $118.7M | $109.4M | $102.0M | $97.4M | $74.7M | $50.3M | $42.8M | $34.8M | $30.8M | $27.9M |
| Average payables | $17.1M | $17.4M | $15.5M | $12.9M | $10.5M | $11.6M | $13.6M | $14.5M | $11.1M | $8.1M |
| Average inventory | $139.1M | $114.8M | $100.2M | $97.3M | $81.6M | $61.5M | $53.4M | $45.0M | $36.3M | $46.5M |
| Intangibles / total assets | 30.7% | 27.4% | 41.1% | 41.9% | 37.1% | 15.4% | 24.5% | 9.0% | 17.6% | 23.9% |
Computed from PCRX's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PCRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Pacira BioSciences traded at 165.7 times earnings, against a 10-year median of 65.4. Based on the latest twelve months, the trailing P/E is 103.8 and the forward P/E is 6.2. Pacira BioSciences earned a return on equity of 1.0% and a return on invested capital of 1.8% in fiscal 2025. It ended the year with $454.4 million of debt and $238.4 million in cash and short-term investments, net debt of $216.0 million. It returned $148.3 million to shareholders: $0 in dividends and $148.3 million in share buybacks, 109% of free cash flow. The share count rose 21.0% from 37.2M to 45.0M over 9 years.
See the PCRX income statement, the PCRX chart for price history, or the PCRX stock overview for the latest quote and news.
PCRX key metrics FAQ
What is Pacira BioSciences's P/E ratio?
Pacira BioSciences's trailing P/E ratio is 103.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 6.2. At the end of fiscal 2025 it was 165.7, compared with a 10-year median of 65.4.
What is Pacira BioSciences's EV/EBITDA?
Pacira BioSciences's enterprise value was 11.3 times EBITDA at the end of fiscal 2025 (enterprise value $1.4 billion, EBITDA $122.5 million); the current EV/EBITDA is 9.8.
What is Pacira BioSciences's return on equity?
Pacira BioSciences's return on equity (ROE) was 1.0% in fiscal 2025: net income of $7.0 million on average shareholders' equity of $735.7 million.
What is Pacira BioSciences's ROIC?
Pacira BioSciences's return on invested capital was 1.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Pacira BioSciences have?
Pacira BioSciences had total debt of $454.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.66 and $216.0 million of net debt (1.76 times EBITDA).
Does Pacira BioSciences buy back its shares?
Yes. Pacira BioSciences spent $148.3 million on net share repurchases in fiscal 2025 Shares outstanding changed −2.6% over the year, to 45.0M..
What is Pacira BioSciences's free cash flow yield?
Pacira BioSciences generated $136.7 million of free cash flow in fiscal 2025, a free cash flow yield of 11.7% on its market value at year-end ($1.2 billion).
What is Pacira BioSciences's current ratio?
Pacira BioSciences's current ratio was 4.54 at the end of fiscal 2025: current assets were 4.54 times current liabilities.